Michael J. Hallek

Circulating extracellular vesicles display immunotherapeutic targets and complement circulating tumor DNA in high-risk neuroblastoma

The paper identifies tumor-associated surface markers on circulating extracellular vesicles as complementary biomarkers to circulating tumor DNA in high-risk neuroblastoma.

Systemic MIF facilitates chronic lymphocytic leukemia development independent of its cellular source

This study shows that systemic MIF is critical for CLL development, regardless of its cellular source, as Mif-deficient hosts resist disease despite adaptive transfer of CLL cells.

Single recipient cell tracking of tellurium-labeled extracellular vesicle proteomes (TeLEV) identifies EV-driven immunomodulation

The paper introduces TeLEV, a method to track EV proteomes in immune cells, revealing EV-driven immunomodulation through STAT5-dependent mechanisms.

Reduced CSF1R expression in myeloid cells has limited impact on chronic lymphocytic leukemia progression

This study shows that reducing CSF1R expression in myeloid cells has limited impact on CLL progression, suggesting that targeting CSF1R alone may not be effective for therapy.

Comparative analysis of macrophage feeder systems reveals distinct behaviors and key transcriptional shifts in chronic lymphocytic leukemia cells via coculture

The paper compares macrophage feeder systems to assess their effects on chronic lymphocytic leukemia cells, including phagocytosis, treatment resistance, and transcriptional changes.

Focal adhesion pathway inhibition is the central axis of macrophage phenotypic responses to monoclonal antibody therapy in aggressive lymphoma via high-throughput screening and high-content imaging

This study identifies focal adhesion pathway inhibition as a key mechanism enhancing macrophage phagocytosis and improving anti-CD20 monoclonal antibody therapy in aggressive lymphoma through high-throughput screening and high-content imaging.

The proteome of small urinary extracellular vesicles after kidney transplantation as an indicator of renal cellular biology and a source for markers predicting outcome

This study identifies PCK2 as a biomarker for renal function 12 months after living donor kidney transplantation using proteomic analysis of urinary extracellular vesicles.